

Ernesto Llano

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1214320/ernesto-llano-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11 papers	207 citations	7 h-index	12 g-index
12 ext. papers	280 ext. citations	3.8 avg, IF	2.96 L-index

#	Paper	IF	Citations
11	Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-IL22 and anti-PD1 antibodies 2019 , 7, 1		75
10	Normal-weight obesity: implications for cardiovascular health. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 464	6	40
9	The obesity paradox and survivors of ischemic stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015 , 24, 1443-50	2.8	32
8	Mechanisms of adverse cardiometabolic consequences of obesity. <i>Current Atherosclerosis Reports</i> , 2013 , 15, 364	6	16
7	Outcomes of endoscopic treatment of leaks and fistulae after sleeve gastrectomy: results from a large multicenter U.S. cohort. <i>Surgery for Obesity and Related Diseases</i> , 2019 , 15, 850-855	3	13
6	Microbial Sensing by Intestinal Myeloid Cells Controls Carcinogenesis and Epithelial Differentiation. <i>Cell Reports</i> , 2018 , 24, 2342-2355	10.6	9
5	How Drug Shortages Affect Clinical Care: The Case of the Surgical Anesthetic Propofol. <i>Hospital Pharmacy</i> , 2015 , 50, 798-805	1.1	8
4	deficiency results in colitis susceptibility. <i>ELife</i> , 2019 , 8,	8.9	6
3	Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease.. <i>Crohn's & Colitis 360</i> , 2022 , 4, otac002	1.4	3
2	Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers. <i>Pancreatology</i> , 2020 , 20, 1747-1754	3.8	3
1	Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease. <i>Crohn's & Colitis 360</i> , 2021 , 3,	1.4	2